{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:21:20Z","timestamp":1793373680743,"version":"4.5.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007322","name":"Fox Chase Cancer Center","doi-asserted-by":"publisher","award":["3P30CA006927"],"award-info":[{"award-number":["3P30CA006927"]}],"id":[{"id":"10.13039\/100007322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["3P30CA006927"],"award-info":[{"award-number":["3P30CA006927"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.eururo.2024.06.018","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:24:01Z","timestamp":1720916641000},"page":"297-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial"],"prefix":"10.1016","volume":"86","author":[{"given":"Elizabeth R.","family":"Plimack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Tangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Plets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutika","family":"Kokate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Nabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Grundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woonyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin P.N.","family":"Dinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Ling C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scott Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Theodorescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Goldkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Flaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.06.018_b0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/cancers15010168","article-title":"Predicting complete response to neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"15","author":"Miyagi","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2024.06.018_b0010","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.06.018_b0015","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.06.018_b0020","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2020.02.003","article-title":"Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"3","author":"Miron","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.06.018_b0025","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","article-title":"A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695)","volume":"27","author":"Flaig","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.06.018_b0030","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg2263","article-title":"ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer","volume":"9","author":"Zhou","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.eururo.2024.06.018_b0035","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","article-title":"ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.06.018_b0040","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2024.06.018_b0045","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2023.41.6_suppl.438","article-title":"A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN)","volume":"41","author":"Geynisman","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824024539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824024539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:52:47Z","timestamp":1777549967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824024539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0302283824024539"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.06.018","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}